Role of adalimumab, a novel TNF antagonist, in advancing rheumatoid arthritis control

Drugs of Today

Volumn 39, Issue SUPPL. B, 2003, Pages 17-23

  Emery, Paul ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; METHOTREXATE;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG APPROVAL; DRUG EFFICACY; EUROPE; FOOD AND DRUG ADMINISTRATION; HUMAN; INFECTION; LYMPHOMA; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0345307623     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. Weinblatt, M.E., Keystone, E.C., Furst, D.E. et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003, 48: 35-45.
2. Keystone, E., Sharp, J., Hua, Y. et al. Adalimumab (D2E7), a fully human anti-TNF-α monoclonal antibody, inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy. Arthritis Rheum 2002, 46: S144.
3. van de Putte, L.B., Atkins, C., Malaise, M. et al. Adalimumab (D2E7) monotherapy in the treatment of patients with severely active rheumatoid arthritis. Arthritis Rheum 2002, 46: S144.
4. Furst, D.E., Fleischmann, R., Birbara, C. et al. Efficacy of adalimumab (D2E7), a fully human anti-TNF monoclonal antibody, administered to rheumatoid arthritis patients in combination with other antirheumatic therapy in the STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) trial. Ann Rheum Dis 2002, 61(Suppl. 1): 174.
5. Schiff, M., Furst, D., Kavanaugh, A. et al. Efficacy of adalimumab measured by the disease activity score 28 (DAS28) and EULAR response criteria. Ann Rheum Dis 2003, 62(Suppl. 1): 170.
6. Keystone, E. Kavanaugh, A., Fischkoff, S. Response to adalimumab in patients with early versus late rheumatoid arthritis. Ann Rheum Dis 2003, 62(Suppl. 1): 170.
7. Breedveld, F.C., Allaart, C.F., Rau, R. et al. Sustained efficacy over 4 years with adalimumab in patients with active rheumatoid arthritis. Ann Rheum Dis 2003, 62(Suppl. 1): 169.
8. Burmester, G.R., van de Putte, L.B.A., Rau, R., Schattenkirchner, M., Hartz, D., Kupper, H. Sustained efficacy of adalimumab monotherapy for more than four years in DMARD-refractory RA. Ann Rheum Dis 2003, 62(Suppl. 1): 192.
9. Strand, V., Weisman, M.H., Nichol, M.B., Knight, T.K., Chang, K., Chartash, E.K. Adalimumab improves health-related quality of life in rheumatoid arthritis patients. Ann Rheum Dis 2003, 62(Suppl. 1): 356.
10. Data on file.
11. Chartash, E.K., Vasey, F.B., Yount, S., Cella, D., Sengupta, N. Adalimumab improves fatigue in patients with active rheumatoid arthritis. Ann Rheum Dis 2003, 62(Suppl. 1): 349.